A privately held Shanghai RNAi company founded in 2021 by Stella Shi, with liver-targeted siRNA drugs in the clinic for cardiovascular and metabolic disease, which in October 2026 licensed worldwide rights to an ALK7 obesity candidate from its extrahepatic delivery platform to Roche.
A privately held Shanghai RNAi company founded in 2021 by Stella Shi, with liver-targeted siRNA drugs in the clinic for cardiovascular and metabolic disease, which in October 2026 licensed worldwide rights to an ALK7 obesity candidate from its extrahepatic delivery platform to Roche.
